89 related articles for article (PubMed ID: 27433930)
1. Exploiting tumor vulnerabilities: NAD(+)-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies.
Cea M; Soncini D; Gobbi M; Lemoli RM; Cagnetta A
Expert Rev Anticancer Ther; 2016 Sep; 16(9):897-8. PubMed ID: 27433930
[No Abstract] [Full Text] [Related]
2. [Key role of nicotinamide phosphoribosyltransferase (NAMPT) and NAD metabolism in the transition of melanoma cells to an invasive and drug-resistant phenotype].
Bertolotto C; Ohanna M; Ballotti R
Med Sci (Paris); 2018 Dec; 34(12):1025-1028. PubMed ID: 30623759
[No Abstract] [Full Text] [Related]
3. OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis.
Korotchkina L; Kazyulkin D; Komarov PG; Polinsky A; Andrianova EL; Joshi S; Gupta M; Vujcic S; Kononov E; Toshkov I; Tian Y; Krasnov P; Chernov MV; Veith J; Antoch MP; Middlemiss S; Somers K; Lock RB; Norris MD; Henderson MJ; Haber M; Chernova OB; Gudkov AV
Leukemia; 2020 Jul; 34(7):1828-1839. PubMed ID: 31896781
[TBL] [Abstract][Full Text] [Related]
4. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies.
Nahimana A; Attinger A; Aubry D; Greaney P; Ireson C; Thougaard AV; Tjørnelund J; Dawson KM; Dupuis M; Duchosal MA
Blood; 2009 Apr; 113(14):3276-86. PubMed ID: 19196867
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD
Guo J; Lam LT; Longenecker KL; Bui MH; Idler KB; Glaser KB; Wilsbacher JL; Tse C; Pappano WN; Huang TH
Biochem Biophys Res Commun; 2017 Sep; 491(3):681-686. PubMed ID: 28756225
[TBL] [Abstract][Full Text] [Related]
6. IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies.
Bergaggio E; Riganti C; Garaffo G; Vitale N; Mereu E; Bandini C; Pellegrino E; Pullano V; Omedè P; Todoerti K; Cascione L; Audrito V; Riccio A; Rossi A; Bertoni F; Deaglio S; Neri A; Palumbo A; Piva R
Blood; 2019 Jan; 133(2):156-167. PubMed ID: 30455381
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.
Sociali G; Raffaghello L; Magnone M; Zamporlini F; Emionite L; Sturla L; Bianchi G; Vigliarolo T; Nahimana A; Nencioni A; Raffaelli N; Bruzzone S
Oncotarget; 2016 Jan; 7(3):2968-84. PubMed ID: 26658104
[TBL] [Abstract][Full Text] [Related]
8. EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition.
Zucal C; D'Agostino VG; Casini A; Mantelli B; Thongon N; Soncini D; Caffa I; Cea M; Ballestrero A; Quattrone A; Indraccolo S; Nencioni A; Provenzani A
BMC Cancer; 2015 Nov; 15():855. PubMed ID: 26542945
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
Sampath D; Zabka TS; Misner DL; O'Brien T; Dragovich PS
Pharmacol Ther; 2015 Jul; 151():16-31. PubMed ID: 25709099
[TBL] [Abstract][Full Text] [Related]
10. Metabolism: Totally addicted to NAD(.).
Shipman L
Nat Rev Cancer; 2016 Feb; 16(2):70. PubMed ID: 26743031
[No Abstract] [Full Text] [Related]
11. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.
Tateishi K; Wakimoto H; Iafrate AJ; Tanaka S; Loebel F; Lelic N; Wiederschain D; Bedel O; Deng G; Zhang B; He T; Shi X; Gerszten RE; Zhang Y; Yeh JJ; Curry WT; Zhao D; Sundaram S; Nigim F; Koerner MVA; Ho Q; Fisher DE; Roider EM; Kemeny LV; Samuels Y; Flaherty KT; Batchelor TT; Chi AS; Cahill DP
Cancer Cell; 2015 Dec; 28(6):773-784. PubMed ID: 26678339
[TBL] [Abstract][Full Text] [Related]
12. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777.
Beauparlant P; Bédard D; Bernier C; Chan H; Gilbert K; Goulet D; Gratton MO; Lavoie M; Roulston A; Turcotte E; Watson M
Anticancer Drugs; 2009 Jun; 20(5):346-54. PubMed ID: 19369827
[TBL] [Abstract][Full Text] [Related]
13. [Progress of studies on multidrug resistance in hematological malignancies--review].
Zhang JH; Chen XH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1151-4. PubMed ID: 16403302
[TBL] [Abstract][Full Text] [Related]
14. Could NAMPT inhibition become a potential treatment option in hepatocellular carcinoma?
Garten A; Schuster S; Penke M
Expert Rev Anticancer Ther; 2017 Apr; 17(4):289-291. PubMed ID: 28271737
[No Abstract] [Full Text] [Related]
15. Up-regulation of nicotinamide phosphoribosyltransferase and increase of NAD+ levels by glucose restriction extend replicative lifespan of human fibroblast Hs68 cells.
Yang NC; Song TY; Chang YZ; Chen MY; Hu ML
Biogerontology; 2015 Feb; 16(1):31-42. PubMed ID: 25146190
[TBL] [Abstract][Full Text] [Related]
16. Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption.
Chan M; Gravel M; Bramoullé A; Bridon G; Avizonis D; Shore GC; Roulston A
Cancer Res; 2014 Nov; 74(21):5948-54. PubMed ID: 25145669
[TBL] [Abstract][Full Text] [Related]
17. Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.
Chen H; Wang S; Zhang H; Nice EC; Huang C
Expert Rev Anticancer Ther; 2016 Aug; 16(8):827-38. PubMed ID: 27186719
[TBL] [Abstract][Full Text] [Related]
18. Drug Resistance in Hematological Malignancies.
Auberger P; Tamburini-Bonnefoy J; Puissant A
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32847013
[TBL] [Abstract][Full Text] [Related]
19. Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results.
Bassan R; Chiodini B; Zucchetti M; Lerede T; Cornelli PE; Cortelazzo S; Barbui T
Haematologica; 1998 Jan; 83(1):27-33. PubMed ID: 9542320
[TBL] [Abstract][Full Text] [Related]
20. Targeting NAMPT for Therapeutic Intervention in Cancer and Inflammation: Structure-Based Drug Design and Biological Screening.
Pulla VK; Sriram DS; Soni V; Viswanadha S; Sriram D; Yogeeswari P
Chem Biol Drug Des; 2015 Oct; 86(4):881-94. PubMed ID: 25850461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
